Nový fenotypový klasifikačný systém dyslipidémií založený na štandardnom lipidovom paneli / New phenotypic classification system for dyslipidemias based on the standard lipid panel

Autor: Gaško, Rudolf, Hefler, Margita, Pirošková, Zuzana
Rok vydání: 2022
Předmět:
ISSN: 2013-2468
DOI: 10.5281/zenodo.6457249
Popis: Súhrn Po prehľade doterajších fenotypových klasifikácií dyslipidémií popisujeme nový fenotypový klasifikačný systém dyslipidémií, založený na štandardnom lipidovom paneli - cholesterol, HDL-cholesterol a triacylglyceroly - ktorého autormi sú Maureen Sampson a spolupracovníci (2021) a upravujeme ho na použitie v SI jednotkách. Abstract We describe new phenotypic classification system for dyslipidemias based on the standard lipid panel - cholesterol, HDL-cholesterol and triglycerides - by Maureen Sampson and co-workers (2021) and modify it to use SI units.
{"references":["Adler-Milstein, J., Chen, J.H., Dhaliwal, G. (2021) \"Next-Generation Artificial Intelligence for Diagnosis: From Predicting Diagnostic Labels to \"Wayfinding\"\", JAMA, 326(24):2467–2468. doi:10.1001/jama.2021.22396.","Ahmed, S.M., Clasen, M.E., Donnelly, J.F. (1998) \"Management of dyslipidemia in adults\", American family physician, 57(9):2192-2204.","Berberich, A.J., Hegele, R.A. (2021) \"A modern approach to dyslipidemia\", Endocrine Reviews. doi: 10.1210/endrev/bnab037.","Brown, E.E. et al. (2020) \"Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association\", J Clin Lipidol., Jul-Aug;14(4):398-413. doi: 10.1016/j.jacl.2020.04.011.","Cruz-Bautista, I. et al. (2021) \"Familial hypertriglyceridemia: an entity with distinguishable features from other causes of hypertriglyceridemia\", Lipids Health Dis. 20(1):14. doi: 10.1186/s12944-021-01436-6.","Ďurovcová, E., Mareková, M. (2020) \"Clinical Biochemistry. 2nd edition\", UPJŠ Košice, 275 s. ISBN 978-80-8152-937-5 (pdf)","Fredrickson, D.S., Levy, R.I., Lees, R.S. (1967) \"Fat transport in lipoproteins-an integrated approach to mechanisms and disorders\", New Engl J Med, 276, 34-42.","Gaško, R. (2021) \"Stanovenie LDL-cholesterolu novými rovnicami Martin a Sampson, porovnanie so starým Friedewaldom na reálnych dátach a na umelom súbore\", Vnitr Lek. 67(2):e09-17. doi: 10.36290/vnl.2021.028.","Gaško, R. et al. V akej zhode sú výsledky priameho a počítaného stanovenia LDL-cholesterolu v hraničných hodnotách podľa Európskych odporúčaní (2007)? Multicentrická štúdia. Cardiol Letters 2011; 20(6): 468-475.","Grundy, S.M. et al. (2019) \"2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines\", J Am Coll Cardiol. 73:e285–350. doi.org/10.1016/j.jacc.2018.11.003","Hegele, R.A. et al. (2020) \"Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement\", Lancet Diabetes Endocrinol., Jan;8(1):50-67. doi: 10.1016/S2213-8587(19)30264-5.","Jabor, A., Franeková, J. Kubíček, Z. (2020) \"Principy interpretace laboratorních testů: 2., přepracované a doplněné vydání\", Praha, Grada Publishing, 456 s. ISBN 978-80-271-1272-2.","Kubašta, M. et al. (1972) \"Ke snaze klasifikovat hyperlipidémie do typů podle Fredricksona jen na základě koncentrace cholesterolu a triglyceridů v séru\", Časopis lékařů českých, 111, č. 24, s. 548-551.","Langlois, M.R. et al. (2020) \"European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM\", Clin Chem Lab Med. 58(4):496-517. doi: 10.1515/cclm-2019-1253.","Lippi, G., Plebani, M. (2020) \"A modern and pragmatic definition of Laboratory Medicine\", Clin Chem Lab Med. 28;58(8):1171. doi: 10.1515/cclm-2020-0114.","Mach, F. et al. (2020) \"2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)\", European Heart Journal, 41, Issue 1 111–188. doi.org/10.1093/eurheartj/ehz455","Martín-Campos, J.M. (2021) \"Genetic Determinants of Plasma Low-Density Lipoprotein Cholesterol Levels: Monogenicity, Polygenicity, and \"Missing\" Heritability\", Biomedicines, 9, 1728. doi.org/10.3390/biomedicines9111728","Oravec, S. (2012) \"Hyperlipoproteinémie. Úvod do problematiky porúch metabolizmu lipoproteínov\", Univerzita Komenského v Bratislave. 71 s. ISBN 978-80-223-3290-3.","Quispe, R. et al. (2019) \"Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the Very Large Database of Lipids Studies 6 and 7\", Arch Med Sci, 15 (5): 1195–1202. doi.org/10.5114/aoms.2019.87207","Pallazola, V.A. et al. (2020) \"Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)\", Arch Med Sci, 16 (5): 993–1003. doi.org/10.5114/aoms.2019.86972.","Racek, J. (1999) \"Klinická biochemie\", 1. vyd. Praha: Galén. 316 s. ISBN 80-7262-023-1.","Saadatagah, S. et al. (2021) \"Genetic basis of hypercholesterolemia in adults\", npj Genomic Medicine, 6:28. doi.org/10.1038/s41525-021-00190-z.","Sampson, M. et al. (2021) \"A new phenotypic classification system for dyslipidemias based on the standard lipid panel\", Lipids Health Dis 20, 170. doi.org/10.1186/s12944-021-01585-8","Sampson, M. et al. (2020) A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiology, E1–E9. doi:10.1001/jamacardio.2020.0013","Sathiyakumar, V. et al. (2020) \"Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey\", Arch Med Sci. 16(6):1279-1287. doi:10.5114/aoms.2019.86964","Sniderman, A. et al. (2007) \"Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B\", J Clin Lipidol, 1(4):256-63. doi: 10.1016/j.jacl.2007.07.006.","Sniderman, A.D. , Tsimikas, S., Fazio, S. (2014) \"The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies\", J Am Coll Cardiol. 63(19):1935-47. doi: 10.1016/j.jacc.2014.01.060.","Sweeney, T. et al. (2021) \"The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: a Review\", Expert Rev Precis Med Drug Dev, 6(4):247-258. doi: 10.1080/23808993.2021.1930531.","Varghese, B. et al. (2021) \"Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm\", Journal of Clinical Lipidology, 15,1:104-115.e9, doi.org/10.1016/j.jacl.2020.09.011.","Visseren, F.L.J. et al. (2021) \"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice\", European Heart Journal, 42, 3227-3337. doi:10.1093/eurheartj/ehab484","Yano, M. et al. (2019) \"Comparison of Two Homogeneous LDL-Cholesterol Assays Using Fresh Hypertriglyceridemic Serum and Quantitative Ultracentrifugation Fractions\", J Atheroscler Thromb. 26(11):979-988. doi: 10.5551/jat.47191.","Zima, T. et al. (2013) \"Laboratorní diagnostika. Třetí, doplněné a přepracované vydání\", Praha, Galén. 906 s. ISBN 978-80-7492-074-5 (pdf)","WHO Memorandum (1970) Classification of Hyperlipidaemias and Hyperlipoproteinaemias. Bull. Wld. Hlth. Org. 43, 891–915.","Lipidový konsenzus – 2. Odporúčania pre optimálnu diagnostiku a liečbu dyslipoproteinémií u dospelých (2003) Interná med. 3 (1): 10-18","Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease: prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992; 2: 113-156."]}
Databáze: OpenAIRE
Externí odkaz: